Breaking News Instant updates and real-time market news.

PEYUF

Peyto Exploration

$5.80 /

-0.058 (-0.99%)

16:04
06/14/21
06/14
16:04
06/14/21
16:04

Peyto Exploration upgraded to Outperform from Sector Perform at Scotiabank

Scotiabank analyst Cameron Bean upgraded Peyto Exploration to Outperform from Sector Perform with a C$10 price target.

PEYUF Peyto Exploration
$5.80 /

-0.058 (-0.99%)

05/14/21 Stifel
Peyto Exploration price target raised to C$9.75 from C$8.75 at Stifel
04/15/21 Scotiabank
Peyto Exploration price target raised to C$8 from C$6.50 at Scotiabank
03/16/21 Raymond James
Peyto Exploration upgraded to Outperform from Market Perform at Raymond James
03/10/21 CIBC
Peyto Exploration price target raised to C$7 from C$6 at CIBC

TODAY'S FREE FLY STORIES

Earnings
OGE Energy backs FY21 EPS in 'lower half' of $1.76-$1.86, consensus $2.18 » 07:51
08/05/21
08/05
07:51
08/05/21
07:51
OGE

OGE Energy

$34.10 /

-0.265 (-0.77%)

The company reaffirms its…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
OGE OGE Energy
$34.10 /

-0.265 (-0.77%)

OGE OGE Energy
$34.10 /

-0.265 (-0.77%)

06/11/21 BofA
OGE Energy upgraded to Buy from Neutral at BofA
05/25/21 Barclays
OGE Energy upgraded to Equal Weight from Underweight at Barclays
03/11/21 BofA
OGE Energy downgraded to Neutral from Buy at BofA
03/09/21 Wells Fargo
OGE Energy downgraded to Equal Weight at Wells Fargo
OGE OGE Energy
$34.10 /

-0.265 (-0.77%)

Earnings
Provention Bio reports Q2 EPS (46c), consensus (52c) » 07:51
08/05/21
08/05
07:51
08/05/21
07:51
PRVB

Provention Bio

$6.02 /

-0.195 (-3.14%)

Provention Bio expects…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
PRVB Provention Bio
$6.02 /

-0.195 (-3.14%)

PRVB Provention Bio
$6.02 /

-0.195 (-3.14%)

07/09/21 Chardan
Provention Bio coverage transferred at Chardan
05/28/21 Chardan
Provention Bio price target lowered to $22.50 from $35 at Chardan
05/25/21 SVB Leerink
Provention Bio briefing documents a positive, says SVB Leerink
05/07/21 Cantor Fitzgerald
Provention Bio price target lowered to $19 from $25 at Cantor Fitzgerald
PRVB Provention Bio
$6.02 /

-0.195 (-3.14%)

  • 14
    Jan
PRVB Provention Bio
$6.02 /

-0.195 (-3.14%)

PRVB Provention Bio
$6.02 /

-0.195 (-3.14%)

Recommendations
Allogene Therapeutics price target lowered to $44 from $52 at Oppenheimer » 07:51
08/05/21
08/05
07:51
08/05/21
07:51
ALLO

Allogene Therapeutics

$22.13 /

+0.23 (+1.05%)

Oppenheimer analyst Mark…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ALLO Allogene Therapeutics
$22.13 /

+0.23 (+1.05%)

ALLO Allogene Therapeutics
$22.13 /

+0.23 (+1.05%)

05:29 Today Oppenheimer
Allogene Therapeutics price target lowered to $44 from $52 at Oppenheimer
06/21/21 Jefferies
Allogene Therapeutics assumed with a Buy at Jefferies
05/20/21 Jefferies
Allogene update exceeds expectation 'on all fronts,' says Jefferies
05/20/21 Stifel
Allogene data 'better than they appear on the surface,' says Stifel
ALLO Allogene Therapeutics
$22.13 /

+0.23 (+1.05%)

ALLO Allogene Therapeutics
$22.13 /

+0.23 (+1.05%)

Earnings
Arbutus Biopharma reports Q2 EPS (23c), consensus (22c) » 07:51
08/05/21
08/05
07:51
08/05/21
07:51
ABUS

Arbutus Biopharma

$2.76 /

+0.01 (+0.36%)

Reports Q2 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ABUS Arbutus Biopharma
$2.76 /

+0.01 (+0.36%)

ABUS Arbutus Biopharma
$2.76 /

+0.01 (+0.36%)

06/28/21 JMP Securities
Arbutus EASL updates still support progress in Chronic HBV, says JMP Securities
03/10/21 B. Riley Securities
Arbutus Biopharma price target lowered to $7 from $8 at B. Riley Securities
12/17/20 H.C. Wainwright
Arbutus Biopharma initiated with a Buy at H.C. Wainwright
09/15/20 Chardan
Arbutus HBV data 'could represent a turning point,' says Chardan
ABUS Arbutus Biopharma
$2.76 /

+0.01 (+0.36%)

ABUS Arbutus Biopharma
$2.76 /

+0.01 (+0.36%)

Earnings
Stratasys sees Q3 revenue growth 17% - 18% growth year-over-year » 07:51
08/05/21
08/05
07:51
08/05/21
07:51
SSYS

Stratasys

$19.70 /

+0.07 (+0.36%)

Sees Q3 revenue of…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
SSYS Stratasys
$19.70 /

+0.07 (+0.36%)

SSYS Stratasys
$19.70 /

+0.07 (+0.36%)

03/26/21 Lake Street
Desktop Metal initiated with a Sell at Lake Street
03/12/21 Lake Street
Stratasys initiated with a Buy at Lake Street
03/10/21 JPMorgan
Stratasys upgraded to Neutral after 50% pullback at JPMorgan
03/10/21 JPMorgan
Stratasys upgraded to Neutral from Underweight at JPMorgan
SSYS Stratasys
$19.70 /

+0.07 (+0.36%)

  • 03
    Mar
SSYS Stratasys
$19.70 /

+0.07 (+0.36%)

SSYS Stratasys
$19.70 /

+0.07 (+0.36%)

Upgrade
Morgan Stanley upgrades Virtus Investment to Overweight on better EPS growth » 07:51
08/05/21
08/05
07:51
08/05/21
07:51
VRTS

Virtus Investment

$285.16 /

+3.42 (+1.21%)

Morgan Stanley analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
VRTS Virtus Investment
$285.16 /

+3.42 (+1.21%)

VRTS Virtus Investment
$285.16 /

+3.42 (+1.21%)

05:16 Today Morgan Stanley
Virtus Investment upgraded to Overweight from Equal Weight at Morgan Stanley
02/03/21 Barclays
Virtus Investment price target raised to $315 from $280 at Barclays
01/25/21 Barclays
Virtus Investment price target raised to $280 from $270 at Barclays
10/26/20 Barclays
Virtus Investment price target raised to $215 from $180 at Barclays
VRTS Virtus Investment
$285.16 /

+3.42 (+1.21%)

Earnings
InflaRx reports Q2 EPS (EUR0.33) vs. (EUR0.38) last year » 07:50
08/05/21
08/05
07:50
08/05/21
07:50
IFRX

InflaRx

$2.49 /

-0.03 (-1.19%)

"I am very pleased…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
IFRX InflaRx
$2.49 /

-0.03 (-1.19%)

IFRX InflaRx
$2.49 /

-0.03 (-1.19%)

03/26/21 H.C. Wainwright
InflaRx price target lowered to $10 from $12 at H.C. Wainwright
03/11/21 Guggenheim
InflaRx upgraded to Buy from Neutral at Guggenheim
01/12/21 H.C. Wainwright
InflaRx price target raised to $12 from $11 at H.C. Wainwright
11/06/20 SVB Leerink
InflaRx upgraded to Outperform from Market Perform at SVB Leerink
IFRX InflaRx
$2.49 /

-0.03 (-1.19%)

  • 25
    Feb
Earnings
OGE Energy reports Q2 EPS 56c, consensus 53c » 07:50
08/05/21
08/05
07:50
08/05/21
07:50
OGE

OGE Energy

$34.10 /

-0.265 (-0.77%)

Reports Q2 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
OGE OGE Energy
$34.10 /

-0.265 (-0.77%)

OGE OGE Energy
$34.10 /

-0.265 (-0.77%)

06/11/21 BofA
OGE Energy upgraded to Buy from Neutral at BofA
05/25/21 Barclays
OGE Energy upgraded to Equal Weight from Underweight at Barclays
03/11/21 BofA
OGE Energy downgraded to Neutral from Buy at BofA
03/09/21 Wells Fargo
OGE Energy downgraded to Equal Weight at Wells Fargo
OGE OGE Energy
$34.10 /

-0.265 (-0.77%)

Earnings
Quanta Services reports Q2 adjusted EPS $1.06, consensus $1.04 » 07:50
08/05/21
08/05
07:50
08/05/21
07:50
PWR

Quanta Services

$89.05 /

-2.17 (-2.38%)

Reports Q2 revenue $3B,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
PWR Quanta Services
$89.05 /

-2.17 (-2.38%)

PWR Quanta Services
$89.05 /

-2.17 (-2.38%)

07/22/21 Citi
Citi opens 'positive catalyst watch' on Quanta Services into earnings
07/19/21 Cowen
Quanta Services initiated with an Outperform at Cowen
06/25/21 Citi
Citi sees infrastructure framework as 'tailwind' for infrastructure companies
06/08/21
Fly Intel: Top five analyst initiations
PWR Quanta Services
$89.05 /

-2.17 (-2.38%)

PWR Quanta Services
$89.05 /

-2.17 (-2.38%)

PWR Quanta Services
$89.05 /

-2.17 (-2.38%)

PWR Quanta Services
$89.05 /

-2.17 (-2.38%)

Recommendations
Sealed Air price target raised to $62 from $52 at BMO Capital » 07:50
08/05/21
08/05
07:50
08/05/21
07:50
SEE

Sealed Air

$57.99 /

-0.54 (-0.92%)

BMO Capital analyst Mark…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SEE Sealed Air
$57.99 /

-0.54 (-0.92%)

SEE Sealed Air
$57.99 /

-0.54 (-0.92%)

08/03/21 BofA
Sealed Air price target raised to $72 from $67 at BofA
05/06/21 BMO Capital
Sealed Air price target raised to $52 from $42 at BMO Capital
05/05/21
Fly Intel: Top five analyst upgrades
05/05/21 Baird
Sealed Air price target raised to $72 from $56 at Baird
SEE Sealed Air
$57.99 /

-0.54 (-0.92%)

SEE Sealed Air
$57.99 /

-0.54 (-0.92%)

General news
Treasury Market Outlook: Treasuries and EGBs have recouped earlier losses » 07:50
08/05/21
08/05
07:50
08/05/21
07:50
$ECON

Economic Data

/

+

Treasury Market Outlook:…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
$ECON Economic Data
/

+

$ECON Economic Data
/

+

Earnings
Strongbridge maintains FY21 revenue guidance $34M-$36M, consensus $36.28M » 07:50
08/05/21
08/05
07:50
08/05/21
07:50
SBBP

Strongbridge Biopharma

$2.30 /

-0.07 (-2.95%)

The Company maintains…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SBBP Strongbridge Biopharma
$2.30 /

-0.07 (-2.95%)

SBBP Strongbridge Biopharma
$2.30 /

-0.07 (-2.95%)

05/25/21 Craig-Hallum
Strongbridge downgraded to Hold at Craig-Hallum on Xeris acquisition
05/25/21 Craig-Hallum
Strongbridge Biopharma downgraded to Hold from Buy at Craig-Hallum
05/25/21 Mizuho
Xeris Pharmaceuticals price target lowered to $9 from $14 at Mizuho
05/25/21 JMP Securities
Strongbridge downgraded to Market Perform from Outperform at JMP Securities
SBBP Strongbridge Biopharma
$2.30 /

-0.07 (-2.95%)

  • 17
    Sep
SBBP Strongbridge Biopharma
$2.30 /

-0.07 (-2.95%)

Hot Stocks
Dyne Therapeutics expects cash to fund requirements into 2H24 » 07:49
08/05/21
08/05
07:49
08/05/21
07:49
DYN

Dyne Therapeutics

$18.32 /

+0.76 (+4.33%)

Cash, cash equivalents…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
DYN Dyne Therapeutics
$18.32 /

+0.76 (+4.33%)

DYN Dyne Therapeutics
$18.32 /

+0.76 (+4.33%)

03/05/21 Stifel
Dyne Therapeutics weakness a buying opportunity, says Stifel
02/09/21
Dyne Therapeutics initiated with a Buy at JonesTrading
01/07/21 Piper Sandler
Dyne Therapeutics potential beneficiary of Sarepta's SRP-9001 miss, says Piper
10/12/20 Jefferies
Dyne Therapeutics initiated with a Buy at Jefferies
DYN Dyne Therapeutics
$18.32 /

+0.76 (+4.33%)

  • 21
    Jan
  • 17
    Sep
DYN Dyne Therapeutics
$18.32 /

+0.76 (+4.33%)

Earnings
Dyne Therapeutics reports Q2 EPS (58c), consensus (54c) » 07:49
08/05/21
08/05
07:49
08/05/21
07:49
DYN

Dyne Therapeutics

$18.32 /

+0.76 (+4.33%)

"We were pleased to…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
DYN Dyne Therapeutics
$18.32 /

+0.76 (+4.33%)

DYN Dyne Therapeutics
$18.32 /

+0.76 (+4.33%)

03/05/21 Stifel
Dyne Therapeutics weakness a buying opportunity, says Stifel
02/09/21
Dyne Therapeutics initiated with a Buy at JonesTrading
01/07/21 Piper Sandler
Dyne Therapeutics potential beneficiary of Sarepta's SRP-9001 miss, says Piper
10/12/20 Jefferies
Dyne Therapeutics initiated with a Buy at Jefferies
DYN Dyne Therapeutics
$18.32 /

+0.76 (+4.33%)

  • 21
    Jan
  • 17
    Sep
DYN Dyne Therapeutics
$18.32 /

+0.76 (+4.33%)

Earnings
Stratasys reports Q2 EPS (2c), consensus (7c) » 07:49
08/05/21
08/05
07:49
08/05/21
07:49
SSYS

Stratasys

$19.70 /

+0.07 (+0.36%)

Reports Q2 revenue $147M,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
SSYS Stratasys
$19.70 /

+0.07 (+0.36%)

SSYS Stratasys
$19.70 /

+0.07 (+0.36%)

03/26/21 Lake Street
Desktop Metal initiated with a Sell at Lake Street
03/12/21 Lake Street
Stratasys initiated with a Buy at Lake Street
03/10/21 JPMorgan
Stratasys upgraded to Neutral after 50% pullback at JPMorgan
03/10/21 JPMorgan
Stratasys upgraded to Neutral from Underweight at JPMorgan
SSYS Stratasys
$19.70 /

+0.07 (+0.36%)

  • 03
    Mar
SSYS Stratasys
$19.70 /

+0.07 (+0.36%)

SSYS Stratasys
$19.70 /

+0.07 (+0.36%)

Earnings
Kimbell Royalty Partners reports Q2 EPS 4c, consensus 8c » 07:49
08/05/21
08/05
07:49
08/05/21
07:49
KRP

Kimbell Royalty Partners

$11.08 /

-0.32 (-2.81%)

Reports Q2 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
KRP Kimbell Royalty Partners
$11.08 /

-0.32 (-2.81%)

KRP Kimbell Royalty Partners
$11.08 /

-0.32 (-2.81%)

03/18/21 Wells Fargo
Kimbell Royalty Partners downgraded to Equal Weight at Wells Fargo
03/18/21 Wells Fargo
Kimbell Royalty downgraded to Equal Weight from Overweight at Wells Fargo
KRP Kimbell Royalty Partners
$11.08 /

-0.32 (-2.81%)

Recommendations
Tandem Diabetes price target raised to $140 from $135 at Oppenheimer » 07:49
08/05/21
08/05
07:49
08/05/21
07:49
TNDM

TNDM

/

+

Oppenheimer analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
TNDM TNDM
/

+

TNDM TNDM
/

+

07/21/21 Cowen
Tandem Diabetes transferred with Outperform rating at Cowen
05/27/21 Piper Sandler
Medtronic price target raised to $140 from $130 at Piper Sandler
05/25/21 Barclays
Barclays starts Medical Devices sector with Positive industry view
05/24/21 Barclays
Tandem Diabetes initiated with an Underweight at Barclays
TNDM TNDM
/

+

Earnings
Sempra Energy backs FY21 adjusted EPS view $7.75-$8.35, consensus $8.10 » 07:48
08/05/21
08/05
07:48
08/05/21
07:48
SRE

Sempra Energy

$130.88 /

-1.105 (-0.84%)

Backs FY21 adjusted EPS…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SRE Sempra Energy
$130.88 /

-1.105 (-0.84%)

SRE Sempra Energy
$130.88 /

-1.105 (-0.84%)

07/07/21 Goldman Sachs
Sempra Energy downgraded to Buy from Conviction Buy at Goldman Sachs
06/30/21
Fly Intel: Top five analyst downgrades
06/30/21 BofA
Sempra Energy downgraded to Neutral from Buy at BofA
06/28/21 Mizuho
Sempra Energy price target raised to $154 from $148 at Mizuho
SRE Sempra Energy
$130.88 /

-1.105 (-0.84%)

SRE Sempra Energy
$130.88 /

-1.105 (-0.84%)

SRE Sempra Energy
$130.88 /

-1.105 (-0.84%)

Earnings
Parker-Hannifin sees 2022 adjusted EPS $16.20-$17.00, consensus $17.08 » 07:48
08/05/21
08/05
07:48
08/05/21
07:48
PH

Parker-Hannifin

$303.40 /

-5.96 (-1.93%)

For the fiscal year…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
PH Parker-Hannifin
$303.40 /

-5.96 (-1.93%)

PH Parker-Hannifin
$303.40 /

-5.96 (-1.93%)

08/03/21 Berenberg
Meggitt downgraded to Hold from Buy at Berenberg
08/02/21 Baird
Baird says Parker-Hannifin paid 'robust' price for Meggitt, has good M&A record
06/23/21
Fly Intel: Top five analyst upgrades
06/23/21 KeyBanc
KeyBanc upgrades Parker-Hannifin to Overweight on 'multiyear upcycle'
PH Parker-Hannifin
$303.40 /

-5.96 (-1.93%)

PH Parker-Hannifin
$303.40 /

-5.96 (-1.93%)

Earnings
Strongbridge Biopharma reports Q2 EPS (21c), consensus (10c) » 07:48
08/05/21
08/05
07:48
08/05/21
07:48
SBBP

Strongbridge Biopharma

$2.30 /

-0.07 (-2.95%)

Reports Q2 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SBBP Strongbridge Biopharma
$2.30 /

-0.07 (-2.95%)

SBBP Strongbridge Biopharma
$2.30 /

-0.07 (-2.95%)

05/25/21 Craig-Hallum
Strongbridge downgraded to Hold at Craig-Hallum on Xeris acquisition
05/25/21 Craig-Hallum
Strongbridge Biopharma downgraded to Hold from Buy at Craig-Hallum
05/25/21 Mizuho
Xeris Pharmaceuticals price target lowered to $9 from $14 at Mizuho
05/25/21 JMP Securities
Strongbridge downgraded to Market Perform from Outperform at JMP Securities
SBBP Strongbridge Biopharma
$2.30 /

-0.07 (-2.95%)

  • 17
    Sep
SBBP Strongbridge Biopharma
$2.30 /

-0.07 (-2.95%)

Earnings
Parker-Hannifin reports Q4 adjusted EPS $4.38, consensus $4.32 » 07:47
08/05/21
08/05
07:47
08/05/21
07:47
PH

Parker-Hannifin

$303.40 /

-5.96 (-1.93%)

Reports Q4 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
PH Parker-Hannifin
$303.40 /

-5.96 (-1.93%)

PH Parker-Hannifin
$303.40 /

-5.96 (-1.93%)

08/03/21 Berenberg
Meggitt downgraded to Hold from Buy at Berenberg
08/02/21 Baird
Baird says Parker-Hannifin paid 'robust' price for Meggitt, has good M&A record
06/23/21
Fly Intel: Top five analyst upgrades
06/23/21 KeyBanc
KeyBanc upgrades Parker-Hannifin to Overweight on 'multiyear upcycle'
PH Parker-Hannifin
$303.40 /

-5.96 (-1.93%)

PH Parker-Hannifin
$303.40 /

-5.96 (-1.93%)

Hot Stocks
Arena Pharmaceuticals, Second Genome enter collaboration » 07:47
08/05/21
08/05
07:47
08/05/21
07:47
ARNA

Arena Pharmaceuticals

$59.38 /

-1.02 (-1.69%)

Second Genome announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ARNA Arena Pharmaceuticals
$59.38 /

-1.02 (-1.69%)

ARNA Arena Pharmaceuticals
$59.38 /

-1.02 (-1.69%)

05/18/21 Goldman Sachs
Arena Pharmaceuticals initiated with a Buy at Goldman Sachs
04/27/21 Citi
Arena Pharmaceuticals initiated with a Buy at Citi
04/26/21 Credit Suisse
Arena Pharmaceuticals assumed with an Outperform at Credit Suisse
04/06/21 Evercore ISI
Evercore starts 'compelling' Arena spinoff Longboard at Outperform
ARNA Arena Pharmaceuticals
$59.38 /

-1.02 (-1.69%)

ARNA Arena Pharmaceuticals
$59.38 /

-1.02 (-1.69%)

Recommendations
Stephens raises Ping Identity price target to $35, names a Best Idea » 07:47
08/05/21
08/05
07:47
08/05/21
07:47
PING

Ping Identity

$22.43 /

+0.44 (+2.00%)

Stephens analyst Brian…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
PING Ping Identity
$22.43 /

+0.44 (+2.00%)

PING Ping Identity
$22.43 /

+0.44 (+2.00%)

07/16/21 Mizuho
Ping Identity price target lowered to $29 from $30 at Mizuho
06/11/21 Needham
Needham starts Ping Identity at Hold, sees upside potential 'baked in'
06/11/21 Needham
Ping Identity initiated with a Hold at Needham
05/24/21 Stifel
Ping Identity resumed with a Hold at Stifel
PING Ping Identity
$22.43 /

+0.44 (+2.00%)

  • 10
    Oct
  • 15
    Jun
  • 15
    Dec
PING Ping Identity
$22.43 /

+0.44 (+2.00%)

Recommendations
Verisk Analytics price target raised to $195 from $182 at BMO Capital » 07:47
08/05/21
08/05
07:47
08/05/21
07:47
VRSK

Verisk Analytics

$187.52 /

-0.96 (-0.51%)

BMO Capital analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
VRSK Verisk Analytics
$187.52 /

-0.96 (-0.51%)

VRSK Verisk Analytics
$187.52 /

-0.96 (-0.51%)

07/21/21 Morgan Stanley
Verisk Analytics at good point to add to positions, says Morgan Stanley
07/07/21 RBC Capital
Verisk Analytics assumed with an Outperform at RBC Capital
04/27/21 Jefferies
Verisk could hold strategic review of financial services segment, says Jefferies
03/08/21 Raymond James
Verisk Analytics upgraded to Outperform from Market Perform at Raymond James
VRSK Verisk Analytics
$187.52 /

-0.96 (-0.51%)

VRSK Verisk Analytics
$187.52 /

-0.96 (-0.51%)

Hot Stocks
Cabaletta Bio sees cash, cash equivalents to fund operations into Q4 of 2022 » 07:46
08/05/21
08/05
07:46
08/05/21
07:46
CABA

Cabaletta Bio

$7.00 /

-0.11 (-1.55%)

As of June 30, 2021,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
CABA Cabaletta Bio
$7.00 /

-0.11 (-1.55%)

CABA Cabaletta Bio
$7.00 /

-0.11 (-1.55%)

06/29/21 Mizuho
Cabaletta Bio initiated with a Buy at Mizuho
03/17/21 H.C. Wainwright
Cabaletta Bio price target raised to $22 from $20 at H.C. Wainwright
01/08/21 Chardan
Cabaletta Bio initiated with a Buy at Chardan
10/13/20 H.C. Wainwright
Cabaletta Bio initiated with a Buy at H.C. Wainwright
CABA Cabaletta Bio
$7.00 /

-0.11 (-1.55%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.